Creative Medical Technology Holdings, Inc. announced on March 6, 2024, that they have been granted FDA Orphan Drug Designation for CELZ-101. This innovative therapy is designed to prevent allograft rejection in patients undergoing pancreatic islet cell transplantation.
This designation is a significant milestone in the treatment of brittle Type 1 diabetes, a condition marked by severe blood glucose fluctuations. The recognition from the FDA highlights the critical need that CELZ-101 addresses in the medical field.
This achievement underscores Creative Medical Technology’s commitment to advancing transplantation therapy and improving outcomes for patients with Type 1 diabetes.
Creative Medical Technology Holdings, Inc. (CELZ) Stock Price Update: March 6, 2024 – Potential Rebound on the Horizon
On March 6, 2024, Creative Medical Technology Holdings, Inc. (CELZ) experienced a slight decrease in its stock price, trading near the bottom of its 52-week range and below its 200-day simple moving average. The price of CELZ shares dropped by 0.02% since the market last closed, closing at $4.13.
However, there seems to be a positive momentum for CELZ as the stock has risen by $1.65 in pre-market trading. This indicates that investors are showing interest in the stock and are willing to pay a higher price for it before the market officially opens.
Overall, the performance of CELZ on March 6, 2024, shows a mix of both positive and negative signals. While the stock experienced a slight drop in price during regular trading hours, the pre-market trading activity suggests that there may be potential for a rebound in the near future. Investors should continue to monitor the stock closely to see how it performs throughout the day.
CELZ Stock Reports Decline in Net Income and Earnings – March 6, 2024 Update
On March 6, 2024, CELZ stock experienced a decline in its net income compared to the previous year and quarter. The company reported a net income of -$10.14 million in the past year, which was a decrease of 152.8% from the previous year. In the third quarter, the net income was reported at -$1.45 million, showing a decrease of 31.92% from the previous quarter.
Similarly, the earnings per share (EPS) for CELZ also saw a decline in performance. The EPS was reported at -$9.28 for the past year, marking a decrease of 116.54% compared to the previous year. In the third quarter, the EPS was reported at -$1.02, showing a decrease of 29.93% from the previous quarter.
Unfortunately, the total revenue for CELZ was not available at the time of reporting, making it difficult to assess the overall financial performance of the company on March 6, 2024. However, based on the information provided, it is clear that CELZ stock experienced a decline in net income and earnings per share, indicating potential challenges in the company’s financial performance. Investors and analysts may need to closely monitor CELZ stock and wait for more data to become available in order to make informed decisions about the company’s future prospects. It is important to conduct thorough research and analysis before making any investment decisions, especially in light of the recent financial performance of CELZ.
